OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Uveitis as a Result of MAP Kinase Pathway Inhibition
Lavnish Joshi, Andreas Karydis, Maria Gemenetzi, et al.
Case Reports in Ophthalmology (2013) Vol. 4, Iss. 3, pp. 279-282
Open Access | Times Cited: 42
Lavnish Joshi, Andreas Karydis, Maria Gemenetzi, et al.
Case Reports in Ophthalmology (2013) Vol. 4, Iss. 3, pp. 279-282
Open Access | Times Cited: 42
Showing 1-25 of 42 citing articles:
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Maria E. Cabanillas, Mabel Ryder, Camilo Jiménez
Endocrine Reviews (2019) Vol. 40, Iss. 6, pp. 1573-1604
Open Access | Times Cited: 266
Maria E. Cabanillas, Mabel Ryder, Camilo Jiménez
Endocrine Reviews (2019) Vol. 40, Iss. 6, pp. 1573-1604
Open Access | Times Cited: 266
Trametinib: a MEK inhibitor for management of metastatic melanoma
Piotr Rutkowski, Iwona Ługowska, Hanna Koseła-Paterczyk, et al.
OncoTargets and Therapy (2015), pp. 2251-2251
Open Access | Times Cited: 153
Piotr Rutkowski, Iwona Ługowska, Hanna Koseła-Paterczyk, et al.
OncoTargets and Therapy (2015), pp. 2251-2251
Open Access | Times Cited: 153
Ocular toxicities of MEK inhibitors and other targeted therapies
Neda Stjepanovic, Juan P. Velazquez-Martin, Philippe L. Bédard
Annals of Oncology (2016) Vol. 27, Iss. 6, pp. 998-1005
Open Access | Times Cited: 94
Neda Stjepanovic, Juan P. Velazquez-Martin, Philippe L. Bédard
Annals of Oncology (2016) Vol. 27, Iss. 6, pp. 998-1005
Open Access | Times Cited: 94
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
Adil Daud, Katy K. Tsai
The Oncologist (2017) Vol. 22, Iss. 7, pp. 823-833
Open Access | Times Cited: 82
Adil Daud, Katy K. Tsai
The Oncologist (2017) Vol. 22, Iss. 7, pp. 823-833
Open Access | Times Cited: 82
Taku Fujimura, Yumi Kambayashi, Kayo Tanita, et al.
The Journal of Dermatology (2018) Vol. 45, Iss. 6, pp. 735-737
Closed Access | Times Cited: 72
Drug-induced uveitis
Ramana S. Moorthy, Meena S. Moorthy, Emmett T. Cunningham
Current Opinion in Ophthalmology (2018) Vol. 29, Iss. 6, pp. 588-603
Closed Access | Times Cited: 70
Ramana S. Moorthy, Meena S. Moorthy, Emmett T. Cunningham
Current Opinion in Ophthalmology (2018) Vol. 29, Iss. 6, pp. 588-603
Closed Access | Times Cited: 70
Drug-induced uveitis: A review
Manisha Agarwal, Parthopratim Dutta Majumder, Kalpana Babu, et al.
Indian Journal of Ophthalmology (2020) Vol. 68, Iss. 9, pp. 1799-1799
Open Access | Times Cited: 61
Manisha Agarwal, Parthopratim Dutta Majumder, Kalpana Babu, et al.
Indian Journal of Ophthalmology (2020) Vol. 68, Iss. 9, pp. 1799-1799
Open Access | Times Cited: 61
Drug-induced uveitis
Ramana S. Moorthy, Nikolas London, Sunir J. Garg, et al.
Current Opinion in Ophthalmology (2013) Vol. 24, Iss. 6, pp. 589-597
Closed Access | Times Cited: 71
Ramana S. Moorthy, Nikolas London, Sunir J. Garg, et al.
Current Opinion in Ophthalmology (2013) Vol. 24, Iss. 6, pp. 589-597
Closed Access | Times Cited: 71
BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity
Maria E. Cabanillas, Ami Patel, Brian P. Danysh, et al.
Hormones and Cancer (2014) Vol. 6, Iss. 1, pp. 21-36
Open Access | Times Cited: 64
Maria E. Cabanillas, Ami Patel, Brian P. Danysh, et al.
Hormones and Cancer (2014) Vol. 6, Iss. 1, pp. 21-36
Open Access | Times Cited: 64
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management.
Elisabeth Livingstone, Lisa Zimmer, Julia Vaübel, et al.
PubMed (2014) Vol. 3, Iss. 3, pp. 29-29
Closed Access | Times Cited: 60
Elisabeth Livingstone, Lisa Zimmer, Julia Vaübel, et al.
PubMed (2014) Vol. 3, Iss. 3, pp. 29-29
Closed Access | Times Cited: 60
Ocular toxicity due to Trametinib and Dabrafenib
Stephanie Sarny, M. Neumayer, Julian Kofler, et al.
BMC Ophthalmology (2017) Vol. 17, Iss. 1
Open Access | Times Cited: 58
Stephanie Sarny, M. Neumayer, Julian Kofler, et al.
BMC Ophthalmology (2017) Vol. 17, Iss. 1
Open Access | Times Cited: 58
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
D. Draganova, Joseph Kerger, Laure Caspers, et al.
Journal of Ophthalmic Inflammation and Infection (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 57
D. Draganova, Joseph Kerger, Laure Caspers, et al.
Journal of Ophthalmic Inflammation and Infection (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 57
Ocular Toxicity of Targeted Anticancer Agents
Blake H. Fortes, Prashant D. Tailor, Lauren A. Dalvin
Drugs (2021) Vol. 81, Iss. 7, pp. 771-823
Closed Access | Times Cited: 38
Blake H. Fortes, Prashant D. Tailor, Lauren A. Dalvin
Drugs (2021) Vol. 81, Iss. 7, pp. 771-823
Closed Access | Times Cited: 38
Intermediate Uveitis: An Updated Review of the Differential Diagnosis and Relevant Special Investigations
J Mark, Derrick P. Smit, E Rajashree, et al.
Ocular Immunology and Inflammation (2025), pp. 1-13
Open Access
J Mark, Derrick P. Smit, E Rajashree, et al.
Ocular Immunology and Inflammation (2025), pp. 1-13
Open Access
Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Sara Touhami, Isabelle Audo, C. Terrada, et al.
Progress in Retinal and Eye Research (2019) Vol. 72, pp. 100761-100761
Closed Access | Times Cited: 41
Sara Touhami, Isabelle Audo, C. Terrada, et al.
Progress in Retinal and Eye Research (2019) Vol. 72, pp. 100761-100761
Closed Access | Times Cited: 41
A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy
Stanford Taylor, Frank N. Hrisomalos, Gerald P. Linette, et al.
American Journal of Ophthalmology Case Reports (2016) Vol. 2, pp. 23-25
Open Access | Times Cited: 32
Stanford Taylor, Frank N. Hrisomalos, Gerald P. Linette, et al.
American Journal of Ophthalmology Case Reports (2016) Vol. 2, pp. 23-25
Open Access | Times Cited: 32
Retinal toxicities of systemic anticancer drugs
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, et al.
Survey of Ophthalmology (2021) Vol. 67, Iss. 1, pp. 97-148
Closed Access | Times Cited: 26
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, et al.
Survey of Ophthalmology (2021) Vol. 67, Iss. 1, pp. 97-148
Closed Access | Times Cited: 26
Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series
Ruby A. Parikh, Benjamin Chaon, Meghan Berkenstock
Ocular Immunology and Inflammation (2020) Vol. 29, Iss. 7-8, pp. 1585-1590
Closed Access | Times Cited: 21
Ruby A. Parikh, Benjamin Chaon, Meghan Berkenstock
Ocular Immunology and Inflammation (2020) Vol. 29, Iss. 7-8, pp. 1585-1590
Closed Access | Times Cited: 21
Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective
Menelaos Kanakis, Petros Petrou, Panagiota Lourida, et al.
Survey of Ophthalmology (2021) Vol. 67, Iss. 2, pp. 388-410
Closed Access | Times Cited: 20
Menelaos Kanakis, Petros Petrou, Panagiota Lourida, et al.
Survey of Ophthalmology (2021) Vol. 67, Iss. 2, pp. 388-410
Closed Access | Times Cited: 20
Uveítis y desprendimiento seroso de retina secundarios al tratamiento sistémico con dabrafenib y trametinib
T. Rueda-Rueda, J.L. Sánchez-Vicente, A. Moruno-Rodríguez, et al.
Archivos de la Sociedad Española de Oftalmología (2018) Vol. 93, Iss. 9, pp. 458-462
Closed Access | Times Cited: 23
T. Rueda-Rueda, J.L. Sánchez-Vicente, A. Moruno-Rodríguez, et al.
Archivos de la Sociedad Española de Oftalmología (2018) Vol. 93, Iss. 9, pp. 458-462
Closed Access | Times Cited: 23
Bilateral Ischemic Retinal Vasculitis in Metastatic Cutaneous Melanoma Patient Treated with Dabrafenib and Trametinib: A Case Report
Alfredo Niro, Nicola Recchimurzo, Alessandra Sborgia, et al.
Ocular Immunology and Inflammation (2016) Vol. 26, Iss. 5, pp. 783-785
Closed Access | Times Cited: 20
Alfredo Niro, Nicola Recchimurzo, Alessandra Sborgia, et al.
Ocular Immunology and Inflammation (2016) Vol. 26, Iss. 5, pp. 783-785
Closed Access | Times Cited: 20
Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis
Mathilde Berger, Mona Amini‐Adlé, Delphine Maucort‐Boulch, et al.
Cancer Medicine (2020) Vol. 9, Iss. 8, pp. 2611-2620
Open Access | Times Cited: 19
Mathilde Berger, Mona Amini‐Adlé, Delphine Maucort‐Boulch, et al.
Cancer Medicine (2020) Vol. 9, Iss. 8, pp. 2611-2620
Open Access | Times Cited: 19
Ocular side effects of Trametinib and Dabrafenib: a case report
Bilge Tarım, Meltem Kılıç
Journal of Ophthalmic Inflammation and Infection (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Bilge Tarım, Meltem Kılıç
Journal of Ophthalmic Inflammation and Infection (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Intravitreal Steroid Treatment for Uveitis Associated with Dabrafenib and Trametinib for Metastatic Cutaneous Melanoma
Nora Woltsche, Michael Kruger, Martin Weger, et al.
Ocular Immunology and Inflammation (2020) Vol. 29, Iss. 5, pp. 845-847
Closed Access | Times Cited: 15
Nora Woltsche, Michael Kruger, Martin Weger, et al.
Ocular Immunology and Inflammation (2020) Vol. 29, Iss. 5, pp. 845-847
Closed Access | Times Cited: 15
Ophthalmic adverse effects of BRAF inhibitors
Clara M. Castillejo Becerra, Wendy M. Smith, Lauren A. Dalvin
European Journal of Ophthalmology (2022) Vol. 33, Iss. 2, pp. 1224-1231
Closed Access | Times Cited: 9
Clara M. Castillejo Becerra, Wendy M. Smith, Lauren A. Dalvin
European Journal of Ophthalmology (2022) Vol. 33, Iss. 2, pp. 1224-1231
Closed Access | Times Cited: 9
